WCAMG
GYRE icon

Woodard & Company Asset Management Group’s Gyre Therapeutics GYRE Stock Holding History

Woodard & Company Asset Management Group’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1
Closed – – 104
2018
Q3 		$0 Hold
1
– – ﹤0.01% 260
2018
Q2 		$47 Hold
1
– – ﹤0.01% 215
2018
Q1 		$0 Hold
1
– – ﹤0.01% 220
2017
Q4 		$0 Buy
+1
New +$51 ﹤0.01% 226

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Woodard & Company Asset Management Group's GYRE Position: Q4 2018 in Review

Woodard & Company Asset Management Group sold out of Gyre Therapeutics (GYRE) in Q4 2018, closing a stake of 1 share.

Woodard & Company Asset Management Group first reported a position in GYRE in Q4 2017 and held it in 4 quarters. The position peaked at $47 in Q2 2018. 65 funds tracked by Wall St. Rank hold GYRE as of Q4 2018.

  • Woodard & Company Asset Management Group reported no remaining Gyre Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Woodard & Company Asset Management Group sold 1 Gyre Therapeutics share in Q4 2018.
  • Woodard & Company Asset Management Group first reported a position in Gyre Therapeutics in Q4 2017 and held it in 4 quarters.
  • Woodard & Company Asset Management Group's Gyre Therapeutics position peaked at $47 in Q2 2018.
  • 65 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2018.

Based on Woodard & Company Asset Management Group's 13F filing for Q4 2018, filed 1 Feb 2019.